Improving Shared Decision-Making in Non-Small Cell Lung Cancer
This study is testing a communication tool designed to help you and your doctor make treatment decisions together for non-small cell lung cancer (NSCLC). It compares using this "shared decision-making conversation tool" to standard care. The goal is to see if the tool improves how well you and your doctor work together to choose your treatment, and if it makes you feel more satisfied with the process. We are looking for 100 adult patients with stage II, III, or IV non-small cell lung cancer who have appointments at Mayo Clinic in Rochester. The study is currently unclear on its recruitment status.
- Study design
- This study will involve about 100 participants and compares two groups: one receiving standard care and another using the shared decision-making conversation tool during their doctor's visit.
- What's involved
- You would attend a standard doctor's visit, either with or without the conversation tool being used. You would then have follow-up appointments at 2 and 6 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants are followed up at 2 and 6 weeks after their study visit.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Konstantinos Leventakos, M.D., Ph.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Effectiveness of the intervention on implementing shared decision makingBaseline (immediately following appointment); 2 weeks post appointment
Effectiveness of the intervention will be assessed using the 9-item Shared Decision Making Questionnaire (SDMQ-9) to evaluate standard of care alone versus using the non-small cell lung cancer (NSCLC) conversation aid plus standard of care. The overall score is the sum of the 9 items, where lower values indicate less perceived shared decision making, and higher scores indicate more perceived shared decision making. Self-reported responses from patients and clinicians will also be collected at multiple timepoints throughout the study.
- Degree of involvement of patients by the clinician in the shared decision makingBaseline (immediately following appointment); 2 weeks post appointment
Evaluated using the 12-item "observing patient involvement" (OPTION12) tool, where reviewers will view and score recorded encounters. The survey tool consists of 12 items scored from 0-4, where 0=no effort and 4=exemplary effort.
- Provider satisfaction with NSCLC choice conversation aidAfter each encounter for the duration of the study, until accrual is reached
Provider satisfaction with each encounter will be assessed with two questions. The first will be answered using a 5-point Likert scale where 1=Not at all satisfied and 5=Completely satisfied. The second will be answered using a 7-point scale where 1=No, I would strongly recommend against it and 7=Yes, I would strongly recommend it. Higher overall scores indicate higher satisfaction with the intervention.